COLUMBUS, Ohio—Visiox Pharmaceuticals, Inc., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates, announced it has merged with Ocuvex Therapeutics, Inc., a privately held ophthalmic pharmaceutical company that is focused on developing and commercializing novel therapies for glaucoma and other disorders. The companies advised that the strategic combination aims to position the newly combined entity as an emerging leader in the eyecare sector with a strong portfolio of ophthalmic medicines.

Financial details were not disclosed, but the announcement indicated that the merged organization will operate under the Ocuvex name, building on Visiox's commitment to serving the ophthalmic market through high-level collaboration with eyecare professionals. Visiox's products, including Omlonti (omidenepag isopropyl ophthalmic solution), PDP-716 (brimonidine) 0.35% and SDN-037 (difluprednate) 0.04%, are expected to grow Ocuvex's market presence and accelerate the commercialization of these therapeutics.

"The combination of Visiox and Ocuvex makes for a perfect match," said Ryan S. Bleeks, chief executive officer of Visiox. "We have reached significant milestones with our products and Ocuvex is in a great position to take these advancements forward and bring them to market faster and emerge as a future leader in eyecare."